.jpg)
Method for predicting the benefit of endocrine therapy in breast cancer
WO2022161984
The CNIO has developed a novel method for predicting the benefit of endocrine therapy alone or in combination with CDK inhibitors in breast cancer. The inventors have found that P27 single-nucleotide polymorphism T2871099G is a predictor of the benefit of endocrine therapy alone or in combination with CDK inhibitors in breast cancer.
The present invention relates to a method to determine the necessity to combine endocrine therapy with CDK4/6 inhibitors, based on P27 T2871099G SNP. The method of the invention helpsto discern which patients are sufficiently well treated with endocrine therapy from those that require combination with CDK inhibitors, in a quick, robust and inexpensive manner. The present invention is, for example, useful in hormone-positive breast cancer and in particular in early breast cancer.